Press Releases

 
Press Releases
  Date Title and Summary View
Jul 25, 2016
--Company Plans to Initiate Phase 3 Study in 2017 Based on Cenicriviroc Meeting Potentially Registrational NASH Fibrosis Endpoint-- --No Difference Seen in Primary Endpoint, Improvement of NAFLD Activity Score-- --Conference Call to be Held Today at 8:30 a.m. Eastern Time-- ...
Jul 24, 2016
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Monday, July 25 to discuss Phase 2b results for cenicriviroc in patients with non-alcoholic steatohepatitis (NASH) and liver fib...
Jun 27, 2016
--Data Published in the Journal PLOS ONE-- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, to...
Jun 16, 2016
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced that data from a liver injury model showed that ceni...
May 31, 2016
SOUTH SAN FRANCISCO, Calif., May 31, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the following conferences in June. Jefferies 2016 Healthcare Conference Presentation date: Thursday, June 9, 2016 Presentation time: 4:30 p.m. ET ...
May 13, 2016
SOUTH SAN FRANCISCO, Calif., May 13, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today announced that data from a study of cenicriviroc (CVC) in participants with liver cirr...
May 9, 2016
SOUTH SAN FRANCISCO, Calif., May 9, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today reported business highlights and financial results for the three months ended March 31, 2016. ...
May 2, 2016
SOUTH SAN FRANCISCO, Calif., May 2, 2016 (GLOBE NEWSWIRE) -- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, will report financial results for the quarter ended March 31, 2016 after market close on Monday May...
May 2, 2016
SOUTH SAN FRANCISCO, Calif., May 2, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced top-line results from a 12-week interim analysis of the Phase 2a ORION study showing t...
Apr 21, 2016
SOUTH SAN FRANCISCO, Calif., April 21, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced upcoming oral data presentations at the International Workshop on NASH Biomarkers i...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase